Kinase Inhibitors

GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP).

GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP).

GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP).

InformationGDC-0879 (AR-00341677) is a novel, potent, and selectiveB-Rafinhibitor withIC50of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well: no inhibition known to other protein kinases.In vitroGDC-0879 also inhibits cellular

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.A potent inhibitor the PI 3-kinase family.

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.A potent inhibitor the PI 3-kinase family.

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.A potent inhibitor the PI 3-kinase family.

GDC-4379 is a JAK1 inhibitor that can be used for the research of asthmaForm:SolidIC50&amp: Target:JAK1.

GDC-4379 is a JAK1 inhibitor that can be used for the research of asthmaForm:SolidIC50&amp: Target:JAK1.

Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies suggest that

Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies suggest that

Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib (ZD1839: HY-50895) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC 50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC 50 of